Stockscreener 앱 받기
2.02
30.82%
-0.90
시간 외 거래:
1.99
-0.03
-1.49%
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Foghorn Therapeutics stock rating cut to Hold by TD Cowen on trial halt - Investing.com Canada
Citizens downgrades Foghorn Therapeutics stock rating on drug discontinuation By Investing.com - Investing.com Canada
Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs - Barron's
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift - Investing.com
Stifel cuts Foghorn Therapeutics stock price target on pipeline shift By Investing.com - Investing.com Canada
Why Is Foghorn Therapeutics Stock Tumbling Today?Foghorn Therapeutics (NASDAQ:FHTX) - Benzinga
Foghorn and Lilly Halt FHD-909 After Phase 1 Data - Minichart
Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review - Yahoo Finance
FHTX Stock Slides As Traders Focus On Cash Runway And Charts - StocksToTrade
FHTX Stock Slides As Traders Eye Key Support Levels - timothysykes.com
Why is Foghorn Therapeutics stock plummeting today? By Investing.com - Investing.com Canada
Foghorn Therapeutics Announces Major Strategic Reprioritization, Layoffs - TipRanks
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug - Yahoo Finance
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities - TradingView
Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities - GlobeNewswire
Enterprise value to EBITDA forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Citizens reiterates Foghorn Therapeutics stock rating on trial data By Investing.com - Investing.com Nigeria
Citizens reiterates Foghorn Therapeutics stock rating on trial data - Investing.com
Foghorn Therapeutics (FHTX) Slips 2.17% to $5.87 as Shares Approach Key Support ZoneStock Buy Zone - dars.gov.et
B. Riley Securities Initiates a Buy Rating on Foghorn Therapeutics (FHTX) - The Globe and Mail
Price to book forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Precision Trading with Foghorn Therapeutics Inc. (FHTX) Risk Zones - Stock Traders Daily
Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet - Yahoo Finance
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95Low Vol Factor - vinanet.vn
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FHTX | US3441741077 - marketscreener.com
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Foghorn Therapeutics (NASDAQ:FHTX) Issues Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Foghorn Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics advances FHD-909 with Lilly and launches oral immunology program in Q2 update - Traders Union
Foghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingView
Lilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock Titan
Foghorn’s lung cancer trial advances; IND targeted for 2027 - stocktitan.net
Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - Investing News Network
Foghorn Therapeutics (FHTX) Jumps 5.4% as Biotech Stock Approaches Key Resistance at $5.10IV Expansion Alert - careplusvn.com
Foghorn Therapeutics (FHTX) Rises 1.77% as Shares Hold Above Key Support at $4.38Dividend Arbitrage - dars.gov.et
Foghorn Therapeutics (FHTX) Slides 4.4% to $4.53, Approaching Key Support LevelOrder Block - vinanet.vn
Foghorn Therapeutics Inc. Revenue Breakdown – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Foghorn Therapeutics (FHTX) Declines 6.4% as Gene Regulation Biotech Tests Key Support at $4.21Force Index - vinanet.vn
FHTX Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline AdvancesCore Business Growth - dars.gov.et
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics (FHTX) Expected to Release Earnings on Tuesday - MarketBeat
0.05%
0.82%
자본화:
|
볼륨(24시간):